Syndax Pharmaceuticals Stock Alpha and Beta Analysis
| SNDX Stock | USD 20.55 0.76 3.57% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Syndax Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Syndax Pharmaceuticals over a specified time horizon. Remember, high Syndax Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Syndax Pharmaceuticals' market risk premium analysis include:
Beta 0.36 | Alpha 0.55 | Risk 3.86 | Sharpe Ratio 0.19 | Expected Return 0.75 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Syndax Pharmaceuticals Backtesting, Syndax Pharmaceuticals Valuation, Syndax Pharmaceuticals Correlation, Syndax Pharmaceuticals Hype Analysis, Syndax Pharmaceuticals Volatility, Syndax Pharmaceuticals History and analyze Syndax Pharmaceuticals Performance. Syndax Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Syndax Pharmaceuticals market risk premium is the additional return an investor will receive from holding Syndax Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Syndax Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Syndax Pharmaceuticals' performance over market.| α | 0.55 | β | 0.36 |
Syndax Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Syndax Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Syndax Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Syndax Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Syndax Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Syndax Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syndax Pharmaceuticals stock market price indicators, traders can identify Syndax Pharmaceuticals position entry and exit signals to maximize returns.
Syndax Pharmaceuticals Return and Market Media
The median price of Syndax Pharmaceuticals for the period between Fri, Oct 31, 2025 and Thu, Jan 29, 2026 is 20.23 with a coefficient of variation of 14.29. The daily time series for the period is distributed with a sample standard deviation of 2.69, arithmetic mean of 18.83, and mean deviation of 2.31. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Syndax Pharmaceuticals Is Up 13.6 percent After FDA Approval Expands Revuforj Use in AML | 11/05/2025 |
2 | Lundbeck sparks bidding war with Alkermes Pfizer closes Metsera deal | 11/14/2025 |
3 | Disposition of 1224 shares by Goldan Keith A. of Syndax Pharmaceuticals subject to Rule 16b-3 | 12/01/2025 |
4 | Revuforj Named Best New Drug at the Scrip Awards 2025 | 12/12/2025 |
5 | Syndax Pharmaceuticals Assessing Valuation After Key ASH Data on Revuforj and Niktimvo - simplywall.st | 12/17/2025 |
6 | Commit To Buy Syndax Pharmaceuticals At 13, Earn 21.5 percent Using Options - Nasdaq | 12/29/2025 |
7 | Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj Outside the U.S. | 01/07/2026 |
8 | Is It Time To Reassess Syndax Pharmaceuticals After Last Years 62.5 percent Share Price Gain | 01/14/2026 |
9 | Several Syndax Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - | 01/22/2026 |
10 | SNDX Mizuho Raises Price Target to 600 and Maintains Outperfo - GuruFocus | 01/27/2026 |
About Syndax Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Syndax or other stocks. Alpha measures the amount that position in Syndax Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Dividend Yield | 0.0223 | 0.0198 | Price To Sales Ratio | 43.02 | 40.87 |
Syndax Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Syndax Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Syndax Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Syndax Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Syndax Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Syndax Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.